Susceptibility of Clostridium species isolated in Japan to fidaxomicin and its major metabolite OP-1118.
暂无分享,去创建一个
[1] I. Michon,et al. Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects , 2015, Clinical Drug Investigation.
[2] C. Liao,et al. Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008–2012, northern Taiwan , 2014, European Journal of Clinical Microbiology & Infectious Diseases.
[3] Kristin E. Burke,et al. Clostridium difficile Infection: A Worldwide Disease , 2014, Gut and liver.
[4] T. Louie,et al. Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] D. Crook,et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. , 2012, The Lancet. Infectious diseases.
[6] E. Goldstein,et al. Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria , 2012, Antimicrobial Agents and Chemotherapy.
[7] D. Gerding,et al. Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection , 2011, Antimicrobial Agents and Chemotherapy.
[8] P. Sears,et al. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. , 2011, Journal of medical microbiology.
[9] Pamela Sears,et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.
[10] T. Louie,et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. , 2010, Microbiology.
[11] T. Louie,et al. OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection , 2008, Antimicrobial Agents and Chemotherapy.
[12] S. Finegold,et al. In Vitro Activities of OPT-80 and Comparator Drugs against Intestinal Bacteria , 2004, Antimicrobial Agents and Chemotherapy.
[13] P. Lawson,et al. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. , 1994, International journal of systematic bacteriology.
[14] Clinical,et al. Performance standards for antimicrobial susceptibility testing , 2019 .